Skip to main content

ARYx Therapeutics Stock Forecast, Price & News

+0.01 (+87.50 %)
(As of 05/14/2021 03:43 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume439,370 shs
Average Volume125,861 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive ARYX News and Ratings via Email

Sign-up to receive the latest news and ratings for ARYx Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

About ARYx Therapeutics

ARYx Therapeutics, Inc. discovers and develops novel therapies for large, chronic, and oral markets. The company uses its RetroMetabolic Drug Design technology to design structurally unique molecules that retain the efficacy of original drugs. Its products in clinical development portfolio include Tecarfarin (ATI-5923), an oral anticoagulant, which is in Phase III clinical development for the treatment of patients who are at risk for the formation of dangerous blood clots; and Budiodarone (ATI-2042), an oral antiarrhythmic agent that is in Phase IIb clinical development for the treatment of atrial fibrillation, a form of irregular heartbeat. The company's other clinical development products comprise ATI-7505, an oral prokinetic agent, which is in Phase IIb clinical development for the treatment of chronic constipation, gastroparesis, functional dyspepsia, irritable bowel syndrome with constipation, and gastroesophageal reflux disease; and ATI-9242, an antipsychotic agent in Phase I clinical development for the treatment of schizophrenia and other psychiatric disorders. It also focuses on ATI-20,000 for metabolic disorders and ATI-24,000 for gastrointestinal disorders that are in discovery stage. ARYx Therapeutics, Inc. was founded in 1997 and is based in Fremont, California.


No headlines for this company have been tracked by

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolOTCMKTS:ARYX
Year FoundedN/A

Sales & Book Value

Annual SalesN/A





Next Earnings DateN/A
OptionableNot Optionable


Overall MarketRank

0.00 out of 5 stars

Medical Sector

1907th out of 2,042 stocks

Pharmaceutical Preparations Industry

745th out of 769 stocks

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

ARYx Therapeutics (OTCMKTS:ARYX) Frequently Asked Questions

What stocks does MarketBeat like better than ARYx Therapeutics?

Wall Street analysts have given ARYx Therapeutics a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but ARYx Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Who are some of ARYx Therapeutics' key competitors?

What is ARYx Therapeutics' stock symbol?

ARYx Therapeutics trades on the OTCMKTS under the ticker symbol "ARYX."

How do I buy shares of ARYx Therapeutics?

Shares of ARYX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ARYx Therapeutics' stock price today?

One share of ARYX stock can currently be purchased for approximately $0.02.

How many employees does ARYx Therapeutics have?

ARYx Therapeutics employs 56 workers across the globe.

What is ARYx Therapeutics' official website?

The official website for ARYx Therapeutics is

Where are ARYx Therapeutics' headquarters?

ARYx Therapeutics is headquartered at 6300 DUMBARTON CIRCLE, FREMONT CA, 94555.

How can I contact ARYx Therapeutics?

ARYx Therapeutics' mailing address is 6300 DUMBARTON CIRCLE, FREMONT CA, 94555. The company can be reached via phone at 510-585-2200.

This page was last updated on 5/16/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.